Marc van Dijk is Senior Strategy Lead in Real World Evidence at UCB Pharma. He is responsible for drugs for rare disease in Neuro Development Disorders that are in early development (i.e., pre-clinical stage). He has worked in the pharmaceutical industry for more than 20 years.
